循环肿瘤DNA液体活检技术在子宫颈癌随访监测中的研究现状与展望

Chinese Journal of Practical Gynecology and Obstetrics ›› 2025, Vol. 41 ›› Issue (12) : 1245-1248.

PDF(891 KB)
PDF(891 KB)
Chinese Journal of Practical Gynecology and Obstetrics ›› 2025, Vol. 41 ›› Issue (12) : 1245-1248. DOI: 10.19538/j.fk2025120118

Author information +
History +

Cite this article

Download Citations

References

[1]
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China,2022[J]. Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[2]
Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer[J]. Lancet, 2007, 370(9590): 890-907. DOI: 10.1016/S0140-6736(07)61416-0.
[3]
Han K, Zou J, Zhao Z, et al. Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer[J]. J Clin Oncol, 2024, 42(4): 431-440. DOI: 10.1200/JCO.23.00954.
[4]
杨鑫鑫, 孟宏学. 微小残留病灶检测在实体瘤中的应用及进展[J]. 临床与实验病理学杂志, 2023, 39(12): 1431-1435. DOI: 10.13315/j.cnki.cjcep.2023.12.005.
[5]
Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy:A step closer to transform diagnosis,prognosis and future of cancer treatments[J]. Mol Cancer, 2022, 21(1): 79. DOI: 10.1186/s12943-022-01543-7.
[6]
Yu D, Li Y, Wang M, et al. Exosomes as a new frontier of cancer liquid biopsy[J]. Mol Cancer, 2022, 21(1): 56. DOI: 10.1186/s12943-022-01509-9.
[7]
Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application[J]. Cancer Discov, 2021, 11(4): 858-873. DOI: 10.1158/2159-8290.CD-20-1311.
[8]
Yu SCY, Jiang P, Peng W, et al. Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma[J]. Proc Natl Acad Sci U S A, 2021, 118(50):E2114937118. DOI: 10.1073/pnas.2114937118.
[9]
Jeannot E, Latouche A, Bonneau C, et al. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer[J]. Clin Cancer Res, 2021, 27(21): 5869-5877. DOI: 10.1158/1078-0432.CCR-21-0625.
[10]
Lee SY, Chae DK, Lee SH, et al. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood[J]. BMC Cancer, 2020, 20(1): 694. DOI: 10.1186/s12885-020-07161-0.
[11]
Mittelstadt S, Kelemen O, Admard J, et al. Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse[J]. Br J Cancer, 2023, 128(11): 2097-2103. DOI: 10.1038/s41416-023-02233-x.
[12]
Zill OA, Banks KC, Fairclough SR, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients[J]. Clin Cancer Res, 2018, 24(15): 3528-3538. DOI: 10.1158/1078-0432.CCR-17-3837.
[13]
Montero-Macías R, Veyer D, Bruneau T, et al. TRANSLACOL project: Nodal human papillomavirus tumoral DNA detection by ddPCR for survival prediction in early cervical cancer patients without pelvic lymph node invasion[J]. J Clin Virol, 2023, 161: 105418. DOI: 10.1016/j.jcv.2023.105418.
[14]
Bhambhani C, Sandford E, Haring CT, et al. Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma[J]. Oral Oncol, 2023, 143: 106436. DOI: 10.1016/j.oraloncology.2023.106436.
[15]
Thangarajah F, Busshoff J, Salamon J, et al. Digital droplet PCR-based qua.jpgication of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer[J]. J Cancer Res Clin Oncol, 2023, 149(14): 12597-12604. DOI: 10.1007/s00432-023-05077-3.
[16]
Campo F, Iocca O, Paolini F, et al. The landscape of circulating tumor HPV DNA and TTMV-HPVDNA for surveillance of HPV-oropharyngeal carcinoma:Systematic review and meta-analysis[J]. J Exp Clin Cancer Res, 2024, 43(1):215. DOI: 10.1186/s13046-024-03137-1.
[17]
Gu Y, Wan C, Qiu J, et al. Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis[J]. PLoS One, 2020, 15(2): e0224001. DOI: 10.1371/journal.pone.0224001.
[18]
Lin C, Liu X, Zheng B, et al. Liquid Biopsy,ctDNA Diagnosis through NGS[J]. Life (Basel), 2021, 11(9):890. DOI: 10.3390/life11090890.
[19]
Naegele S, Ruiz-Torres DA, Zhao Y, et al. Comparing the Diagnostic Performance of Quantitative PCR,Digital Droplet PCR,and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus-Associated Cancers[J]. J Mol Diagn, 2024, 26(3): 179-190. DOI: 10.1016/j.jmoldx.2023.11.007.
[20]
Tarazona N, Gimeno-Valiente F, Gambardella V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer[J]. Ann Oncol, 2019, 30(11): 1804-1812. DOI: 10.1093/annonc/mdz390.
[21]
Herbst J, Pantel K, Effenberger K, et al. Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions[J]. Br J Cancer, 2022, 127(8): 1403-1410. DOI: 10.1038/s41416-022-01868-6.
[22]
Sivars L, Hellman K, Crona GY, et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer[J]. Gynecol Oncol, 2022, 167(1): 107-114. DOI: 10.1016/j.ygyno.2022.07.028.
[23]
Yang HJ, Liu VW, Tsang PC, et al. Qua.jpgication of human papillomavirus DNA in the plasma of patients with cervical cancer[J]. Int J Gynecol Cancer, 2004, 14(5): 903-10. DOI: 10.1111/j.1048-891X.2004.014528.x.
[24]
Carow K, Gölitz M, Wolf M, et al. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA[J]. Int J Mol Sci, 2017, 18(10):2032. DOI: 10.3390/ijms18102032.
[25]
Kang Z, Stevanović S, Hinrichs CS, et al. Circulating Cell-free DNA for Metastatic Cervical Cancer Detection,Genotyping,and Monitoring[J]. Clin Cancer Res, 2017, 23(22): 6856-6862. DOI: 10.1158/1078-0432.CCR-17-1553.
[26]
Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas[J]. Nature, 2014, 506(7488): 371-375.DOI: 10.1038/nature12881.
[27]
Li W, Huang Y, Xiao M, et al. PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer[J]. iScience, 2024, 27(3): 109160. DOI: 10.1016/j.isci.2024.109160.
[28]
Charo LM, Eskander RN, Okamura R, et al. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients[J]. Mol Oncol, 2021, 15(1): 67-79. DOI: 10.1002/1878-0261.12791.
[29]
郭苑莉, 陶莹, 廖凤儿, 等. PIK3CA基因在妇科肿瘤中的突变情况及其与患者中位生存时间的关系[J]. 中国医药导报, 2023, 20(14): 25-28.DOI:10.20047/j.issn1673-7210.2023.14.05.
[30]
Chung TKH, Cheung TH, Yim SF, et al. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women[J]. Gynecol Oncol, 2017, 146(2): 334-339. DOI: 10.1016/j.ygyno.2017.05.038.
[31]
Tian X, Ge D, Zhang F, et al. Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer[J]. Int J Cancer, 2021, 148(4): 921-931. DOI: 10.1002/ijc.33362.
[32]
Dvorská D, Braný D, Nagy B, et al. Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples[J]. Int J Mol Sci, 2019, 20(17):4119. DOI: 10.3390/ijms20174119.
[33]
Yin FF, Wang N, Bi XN, et al. Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer[J]. Virol J, 2016, 13: 60. DOI: 10.1186/s12985-016-0515-5.
[34]
Bu Q, Luo X, He L, et al. Septin9 DNA methylation as a promising biomarker for cervical cancer[J]. J Obstet Gynaecol, 2023, 43(1): 2151356.DOI: 10.1080/01443615.2022.2151356.

Footnotes

利益冲突 所有作者均声明不存在利益冲突

Funding

National Natural Science Foundation of China(82371757)
CAMS Innovation Fund for Medical Sciences(2023-I2M-C&T-B-037)
CAMS Innovation Fund for Medical Sciences(2023-I2M-C&T-B-020)
PDF(891 KB)

Accesses

Citation

Detail

Sections
Recommended

/